The Protein-Transition Capital Map
The hype money is gone. What it left behind is a clearer picture of who actually funds Israeli food-tech — and who's still standing.
The fastest way to understand Israeli food-tech is to follow the capital through its boom and bust. From 2014 to 2023, Israeli alternative-protein companies raised about 1.2 billion dollars — roughly 10 percent of all global investment in the sector, second only to the United States. Total venture funding has since crossed 1.3 billion, per the Good Food Institute Israel. But the headline figure hides a violent cycle, and the shape of that cycle is the real intelligence.
The peak and the crash
2021 and 2022 were the mania. Single rounds ran past 100 million dollars: Future Meat's 347-million-dollar Series B, Remilk's 120-million-dollar round, Aleph Farms' 105 million, Redefine Meat's 135 million. Then the correction hit, and it hit Israel harder than anywhere. Alternative-protein investment in the country fell roughly 78 percent in 2023, from about 454 million dollars to roughly 100 million — nearly double the global drop — worsened by domestic political turmoil, the October 2023 war, and at least one foreign climate fund pulling a planned Israeli food-tech center. Global funding fell about 49 percent again in the first half of 2025.
Who funds it now
The surviving capital base is a mix of specialist food-tech funds, strategic corporates and crossover investors. Names recurring across Israeli rounds include Hanaco Ventures and the UK's Synthesis Capital (both in Redefine Meat and Remilk), CPT Capital, Target Global, and strategic backers such as Danone — which took a stake in Imagindairy — and the Strauss Group, which is both investor and commercial partner. The Kitchen FoodTech Hub, Strauss's incubator, sits at the center of the early-stage map. The most important non-private actor is the state: the Israel Innovation Authority's grant support held steady through the downturn even as venture money collapsed, and food-tech retains its status as a national R&D priority.
Where the money is going
The capital that remains is invested differently than in the boom. Investors have rotated from finished consumer products toward B2B ingredients and enabling technologies — the companies solving taste, texture and, above all, scale-up and cost. They favor leaner businesses that need less repeat capital. That is a healthier market structure than 2021's land-grab, even if the totals are smaller, and the Israel Innovation Authority projects a gradual recovery toward roughly 6 billion dollars of food-tech investment in 2025 and approaching 8 billion in 2026 — without a return to peak mania.
The read
The bust did the industry a favor by clearing it. Believer Meats' closure in December 2025 was the most visible casualty, but the survivors emerged with regulatory approvals, retail partnerships and disciplined burn rates. For patient capital, a sector that has already been repriced, backed by steady government support and oriented toward food security, is a more rational entry than one priced for perfection. The map is smaller now. It is also a great deal more legible.
Part of Olam's Agriculture & Food Tech coverage. See the pillar: Why Israel Bet the Farm on the Protein Transition.
